About CLINUVEL

Thursday, 05 January 2012 04:51

Edison QuickView: Positive in Phase III

Positive results in the second Phase III study of CLINUVEL’s Scenesse (afamelanotide), a photoprotective drug for treating the orphan condition erythropoietic protoporphyria (EPP), put the drug on track for an EU approval filing, due shortly, and could be a contributory factor in the FDA’s decision to conduct a Phase III trial.

To read this full report, download the attached PDF.